Compare AstraZeneca plc (AZN) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Otis Worldwide Corp — how do they compare? AstraZeneca plc trades at $157.8 (market cap $248.14B), while Otis Worldwide Corp trades at $73.57 (market cap $27.80B). The key difference: AstraZeneca plc is far larger — about 8.9× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| AZN | OTIS | |
|---|---|---|
Market Cap | $248.14B | $27.80B |
Sector | Health | Industrials |
52-Week High | $209.48 | $93.62 |
52-Week Low | $147.06 | $69.34 |
Enterprise Value | $275.41B | $35.84B |
Dividend Yield | 2.01% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Otis Worldwide (OTIS) trades at $72.87, down 1.51% over 24 hours, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates but saw margin pressures and full-year guidance cuts. The company maintains strong service segment growth, with 9% organic sales increase, while facing headwinds in new equipment demand and labor costs. Valuation metrics show a P/E of 18.78 and P/S of 1.91, below historical averages after a 19% year-to-date decline.
Outlook is mixed: analyst consensus targets $92.50 with 47% buy ratings, but near-term risks include persistent margin compression and weak equipment sales. Long-term potential hinges on service margin expansion and modernization backlog execution, though investor sentiment remains cautious amid earnings misses and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
